DEPARTMENT OF ONCOLOGY REPORT 2003
DIVISION OF MEDICAL ONCOLOGY – DR. VIVIEN H.C. BRAMWELL, DIVISION CHIEF
INTRODUCTION
The Division of Medical Oncology undertakes scholarly activity and provides clinical care across
the whole spectrum of Tumor Groups (see Clinical Service). The majority of members have fulltime academic appointments in the Department of Oncology, University of Calgary. The
specialty is advancing rapidly in terms of availability of multiple treatments, complexity of those
treatments and range of conditions now treatable. Much of the evidence supporting
recommendations for new systemic therapies is derived from large-scale, multicentre phase III
trials, and members of the Division are both leaders and contributors in this research activity.
The role of the Medical Oncologist is changing and time demands on medical staff are rising
inexorably as patients tend to be much sicker; they are also better informed and increasingly
wish to partner with their Oncologist in formulating treatment plans.
Dr. Bramwell assumed leadership of the Division on January 1st, 2003. A graduate of our
Residency Training Program, Dr. Tina Cheng, joined on April 1st, 2003. Departures were Dr.
Edna Rapp, who retired March 31st; Dr. Scott Ernst, who joined London Regional Cancer
Centre, Ontario, in July; and Dr. Stefan Glück who moved in October, to the University of Miami.
To chart the Division’s future course in this changing climate, a full-day Retreat was held on
March 21st, 2003, entitled “Research to Practice: Barriers to Excellence”. We developed a
vision for Medical Oncology that; “Within ten years, TBCC becomes known as the premier
centre in Canada for the development and delivery of effective research-based clinical care”.
Team effort by members of the Division, with different but important contributions across the
spectrum of clinical practice, research, education and administration, is moving us in the
direction of our vision.
EDUCATION
Drs. Cindy Card and Scot Dowden are each in the second year of study for a Master’s Degree
in Education. Despite significant clinical workloads, each have completed most of their required
courses and are starting work on their theses. Dr. Card is taking on increasing responsibilities
as a lecturer, preceptor and examiner within the Undergraduate Education Program and is CoChair of the Department of Oncology Continuing Medical Education Committee. Dr. Dowden is
coordinator for several aspects of the Medical Oncology Training Program, and is developing a
web-based Continuing Medical Education Program in Oncology.
Dr. Don Morris, as chair of the Postgraduate Education Committee, steered all the Oncology
Residency Programs, including Medical Oncology, through a successful review by the Royal
College of Physicians and Surgeons of Canada.
Three Medical Oncology trainees,
Drs. John Sarantopoulos, Sasha Lupichuk and Margaret Balcewicz, completed their Medical
Oncology training in 2003. All have gone on to undertake research fellowships elsewhere in
Canada or the US. Dr. Sasha Lupichuk will be returning in September 2004, having completed
a one-year Genetics Fellowship at McMaster University in Hamilton, with a plan to complete a
Master’s Degree in Epidemiology. Dr. Laura Chow entered the second year of her two-year
program, and we welcome Drs. Wei Lin, Patricia Tang and Marc Webster to the first year of our
Page 1 of 15
Medical Oncology Fellowship Program. We continue to teach Residents from Internal Medicine,
Neurology and the other Oncology disciplines who rotate through Medical Oncology.
Dr. Peter Forsyth supervised three PhD students, Tommy Alain, Angela McDermid and
Stephen Hanson, as well as four Postdoctoral Fellows, Drs. Wenqing Yang, Donna Senger,
Xueqing Lun and Bo Huang, working in the Brain Tumor Laboratory Program. Dr. Don Morris
supervised two Postdoctoral Fellows, Drs. Chandini Thirukkumaran and Angus Kim, working in
his Translational Research Program.
Dr. Desirée Hao was a member of the American Society of Clinical Oncology Career
Development Committee, and served as a liaison to the Cancer Communications Committee.
She has now become a full member of the latter committee, which oversees public and media
relations for the Society. Dr. Doug Stewart completes a 3-year term as Chair of the
Examination Board for Medical Oncology, Royal College of Physicians and Surgeons of
Canada.
RESEARCH
Translational
Dr. Peter Forsyth’s innovative laboratory and clinical work with reoviruses continues,
supported by multiple grants from Alberta Cancer Board (ACB), National Cancer Institute of
Canada (NCIC), Canadian Institutes of Health Research (CIHR) and Industry. Phase I and II
studies in recurrent malignant gliomas are currently under way. The Brain Tumor Program has
been considerably strengthened by recruitment of Dr. Greg Cairncross into the ACF Chair in
Neuro-Oncology. Dr. Don Morris maintains a program of laboratory and clinical research into
reoviruses, apoptotic pathways in breast and prostate cancer, and graft engineering with stem
cell purging techniques, grant funded by ACB, NCIC, Prostate Cancer Research Foundation
and Industry. Dr. Vivien Bramwell continues a longstanding collaboration with Dr. Ann
Chambers, Canada Research Chair at the University of Western Ontario, to undertake
laboratory and clinical studies of osteopontin in breast cancer. This work is supported by grants
from Canadian Breast Cancer Research Initiative and the Canadian Breast Cancer Foundation.
Clinical Research
During 2003, Medical Oncologists contributed 290 patients to more than 50 clinical trials. A
further 177 patients were recruited into bone marrow transplant protocols. In addition, 51
patients received two promising investigational drugs, Iressa and Alimta, through
compassionate release programs. Samples and clinical data from 51 individuals were
submitted to the Brain Tumor Bank.
Dr. Vivien Bramwell has been Chair of the Canadian Sarcoma Group/NCIC Clinical Trials
Group (NCIC-CTG) Sarcoma Committee for the past eighteen years. In this capacity, she
participated in the 5-year grant renewal process for the Clinical Trials Group, was involved in the
establishment of a US/Canada Sarcoma Intergroup and was part of a 25-member Progress
Review Group in Sarcoma, sponsored by the National Cancer Institute in the US. She is also
the Canadian Principal Investigator for an Intergroup sarcoma adjuvant trial, NCIC-CTG
SR3/EORTC 62931, and is on the Trial Committee for the Canadian-led International breast
cancer adjuvant trial, NCIC-CTG MA-21. Dr. Sandy Paterson is a leading Canadian
Investigator in the National Surgical Adjuvant Breast Project (NSABP) and is currently on their
Board of Directors. He is the Principal Investigator for a large International phase III breast
cancer adjuvant trial, B-34. Dr. Barbara Walley is a North-American Intergroup Chair for the
Page 2 of 15
International Breast Cancer Study Group (IBCSG) trial, 25-02, and is the Canadian Principal
Investigator for two related IBCSG breast cancer adjuvant trials.
Clinical Service
Tumor Group assignments are as follows:
Vivien Bramwell
Cynthia Card
Tina Cheng
Scot Dowden
Peter Forsyth
Desirée Hao
Don Morris
Sandy Paterson
Dean Ruether
James Russell
Doug Stewart
Barbara Walley
Alfred Wong
-
Breast Cancer, Sarcoma
Lung Cancer
Genitourinary Cancer, Melanoma
Gastrointestinal Cancer
Brain Cancer
Lung Cancer, Head and Neck Cancer
Lung Cancer, Sarcoma
Breast Cancer, Neuroendocrine Tumors
Genitourinary Cancer, Breast Cancer, Hematological Malignancies
Allogeneic & Autologous Stem Cell/Bone Marrow Transplantation
Breast Cancer, Lymphoma, Bone Marrow Transplantation
Breast Cancer, Gastrointestinal Cancer
Gastrointestinal Cancer
Medical Oncologists provided leadership to four Tumor Groups – Breast (Dr. S. Glück),
Lymphoma (Dr. D. Stewart), Neurology (Dr. P. Forsyth) and Bone Marrow Transplant (Dr. J.
Russell). The Medical Oncologists are assisted by Drs. Ahsan Chaudhry and Oluyemi Jeje,
who are Ward Physicians for the Bone Marrow Transplant Program and Medical/Radiation
Oncology; Dr. Heather Hicks who continues as a full-time GP Oncologist; and a number of
Clinical Associates (Drs. Tara Pickering, Danelle Hames, Pat Heard, Bryan Brunet, Annie
Claude, Alison Murray, Leslie Coulter and Ardythe Taylor) provide support on a sessional basis.
The Division of Medical Oncology saw approximately 2500 new consultations in 2003, mainly
from within Southern Alberta, but including some referrals from British Columbia and
Saskatchewan. Approximately 10,000 patients made 38,000 visits to the Medical Day Care Unit
to receive chemotherapy and supportive care (blood transfusions, bisphosphonates, etc.) during
2003. Although the majority of these patients are under the care of Medical Oncologists,
Hematologists and Gynecological Oncologists also use the facilities.
Particular thanks are due to Dr. Dean Ruether, our busiest clinician, who has a broad-based
practice which includes monthly clinics in Medicine Hat. He was a great assistance to the
Division, following the departure of Dr. Scott Ernst, in agreeing to change the focus of his
practice to take a leadership role in clinical research and patient care for the very busy
Genitourinary Tumor Group. With the departure of Dr. John Jensen from the Medicine Hat
Associate Cancer Centre, Dr. Tina Cheng stepped in for six months, spending two days a week
in Medicine Hat performing consultations and overseeing chemotherapy. Dr. Alfred Wong
maintains a busy practice in gastrointestinal cancer.
SUMMARY
2003 has been a busy and academically productive year for the Division of Medical Oncology.
Despite significant clinical demands, members of the Division have made diverse contributions
in undergraduate and postgraduate education, translational and clinical research, and research
leadership.
Page 3 of 15
PEER REVIEWED MANUSCRIPTS PUBLISHED IN 2003
Ernest C Borden, Lawrence H Baker, Robert S Bell, Vivien Bramwell, George D Demetri,
Burton L Eisenberg, Christopher DM Fletcher, Jonathan A Fletcher, Marc Landeyni, Paul
Meltzer, Brian O’Sullivan, David R Parkinson, Peter WT Pisters, Scott Saxman, Samuel Singer,
Murali Sundaram, Allan T Van Oosterom, Jaáp Verweij, Jill Waalen, Sharon W Weiss, Murray F
Brennan. Soft tissue sarcomas of adults: state of the translational science. Clinical Cancer
Research 9:1941-1956, 2003.
Elaine S Bouttell, N Wilson Rodger, Vivien HC Bramwell. Metastatic secondary fibrosarcoma
of bone responsive to repeated courses of ifosfamide and associated with hypoglycemia.
Sarcoma 7:81-85, 2003.
Michael Crump, Dongsheng Tu, Lois Shepherd, Mark Levine, Vivien Bramwell, Kathleen
Pritchard. Risk of acute leukaemia following epirubicin-based adjuvant chemotherapy: a report
from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:16, 30663071, 2003.
George N Naumov, Jason L Townson, Ian C MacDonald, Sylvia M Wilson, Vivien HC
Bramwell, Alan C Groom, Ann F Chambers. Ineffectiveness of doxorubicin treatment on solitary
dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Research &
Treatment 82:199-206, 2003.
N Iscoe, V Bramwell, M Charette, T Oliver and the Systemic Treatment Disease Site Group.
Liposomal antrhacyclines in the management of patients with HIV-positive Kaposi sarcoma.
Current Oncology 10(1):17-35, 2003.
Vivien HC Bramwell. Management of advanced adult soft tissue sarcoma. Sarcoma 7:43-45,
2003.
I Quirt, V Bramwell, M Charette, T Oliver and the Cancer Care Ontario Practice Guidelines
Initiative Systemic Treatment Disease Site Group. Role of erythropoietin in the management of
cancer patients with non-hematologic malignancies receiving chemotherapy. Current Oncology
10(2):84-101, 2003.
C Campbell, V Bramwell, M Charette, T Oliver and the Cancer Care Ontario Practice
Guidelines Initiative Systemic Treatment Disease Site Group. Roles of colony-stimulating factor
in patients receiving myelosuppressive chemotherapy for treatment of cancer. Current
Oncology 10(2)102-126, 2003.
Bramwell VH, Anderson D, Charette ML; Sarcoma Disease Site Group. Doxorubicin-based
chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic
soft tissue sarcoma. Cochrane Database Syt Rev. 2003;(3): CDOO3293.
P. Major, A. Figueredo, V. Tandan, V. Bramwell, M. Charette, T. Oliver, and the Systemic
Treatment Disease Site Group. Role of octreotide in the management of patients with cancer.
Current Oncology 10(3): 161-178, 2003.
Cheng T, Forsyth P, Chaudhry A, Morris D, Glück S, Russell JA and Stewart DA. High dose
Thiotepa, Busulfan, Cyclophosphamide and ASCT without whole brain radiotherapy for poor
prognosis primary CNS lymphoma. Bone Marrow Transplant 2003:31, 679-685.
Page 4 of 15
Townsley C, Chi K, Ernst DS, Belanger K, Tannock I, Bjarnason G, Stewart D, Goel R, Siu L,
Jolivet J, McIntosh L, Seymour L, Moore MJ. Troxacitabine, a novel L-nucleoside analog has
modest activity in patients with advanced and/or metastatic renal cell carcinoma. J Clin Oncol
21(8): 1524-9, 2003.
Forsyth P, Weaver S, lton D, Brasher PMA, Sutherland G, Stewart D, Hagen, NA, Barnes P,
Cairncross JG, DeAngelis LM Difficulties in Answering an Important Question in NeuroOncology: Prophylactic Anticonvulsants in Patients With Brain Tumors. The Canadian Journal
of Neurological Sciences. 30: 106-112, 2003. (see editorial in same issue by Mason W.P., pg
89-90).
Nuttall Robert K, Pennington Caroline J, Taplin Jennifer, Wheal Alison, Yong V Wee, Forsyth
Peter, Edwards Dylan R. Elevated Membrane-Type Matrix Metalloproteinases in Gliomas
Revealed by Profiling Proteases and Inhibitors in Human Cancer Cells. Molecular Cancer
Research 1: 333-45, 2003.
Yang W, Senger D, Muzik H, Shi ZQ, Johnson D, Brasher PMA, Rewcastle NB, Hamilton M,
Rutka J, Wolff J, Wetmore C, Curran T, Lee PWK, Forsyth PA. Reovirus prolongs survival and
reduces the frequency of spinal and leptomeningeal metastases from medulloblastoma. Cancer
Research 63, 3162-3172, 2003.
Senger D, Cairncross JG, Forsyth PA. Long-term survivors of glioblastoma: statistical
aberration or important unrecognized molecular subtype? Cancer J. 2003, 9(3):214-21.
Belanger K, MacDonald D, Cairncross G, Gertler S, Forsyth P, Burdette-Radoux S, Bergeron J,
Soulieres D, Ludwin S, Wainman N, Eisenhauer E. A phase II study of topotecan in patients with
anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma. Invest New Drugs. 2003;
21(4):473-80.
Abrey LE, Childs BH, Paleologos N, Kaminer L, Rosenfeld S, Salzman D, Finlay JL, Peterson K,
Hu W, Swinnen L, Bayer R, Forsyth P, Stewart D, Smith AM, Macdonald DR, Weaver S,
Ramsey DA, DeAngelis LM, Cairncross JG. High Dose Chemotherapy With Stem Cell Rescue
as Initial Therapy for Anaplastic Oligodendroglioma. J. Neuro-Oncol 2003, 65(2): 127-134.
Hao D, Hammond LA, Eckhardt SG, et al. A phase I and pharmacokinetic study of squalamine,
an aminosterol angiogenesis inhibitor. Clin Cancer Res 9:2465-2471, 2003.
Alain T, Thirukkmaran C, Morris D, Urbanski S, Janowska-Wieczorek A, Lee P, Kossakowska A.
Lymphomas and Oncolytic Viral Therapy. Clinical Lymphoma 4(2): 1-8, 2003.
Paterson AHG. Taxanes and Primary Operable Breast Cancer: Should These Agents be Used in
Adjuvant Therapy? Oncology Exchange: Vol 2, No 2, (suppl 1) pp20-23, 2003.
Paterson AHG. Bone Metastases: From the Bench to the Bedside: Potential for Prevention. ASCO
Educational Book pp 81- 88, 2003.
Atula S, Powles TJ, Paterson AHG, et al. Extended Safety Profile of Oral Clodronate After LongTerm Use in Primary Breast Cancer Patients. Drug Safety 26:9 pp 661-671, 2003.
Page 5 of 15
Thomas F Hack, Tom Pickles, Barry D Bultz, J Dean Ruether, Lorna M Weir, Lesley F Degner,
and R Mackey. Impact of Providing Audiotapes of Primary Adjuvant Treatment Consultations to
Women With Breast Cancer: A Multisite, Randomized, Controlled Trial. J Clin Oncol 21 (22)
4138-4144, 2003.
Ringden O, Barrett AJ, Zhang M-J, Loberiza FR, Bolwell BJ, Cairo MS, Gale RP, Hale GA, Litzow
MR, Martino R, Russell JA, Tiberghien P, Urbano-Ispizua A, Horowitz MM. Decreased treatment
failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high
CD34 cell doses. Br J Haematol 2003, 121(6):874.
Syme R, Stewart D, Rodriguez-Galvez M, Luider J, Auer Y, Klassen J, Morris D, Brown C,
Russell J, Glück S. Micrometastases in apheresis products predict shorter progression-free
and overall survival in patients with breast cancer undergoing high-dose chemotherapy (HDCT)
and autologous blood stem cell transplantation (ABSCT). Bone Marrow Transplant 2003;32:307311.
Thirukkumaran CM, Luider JM, Stewart, DA, Cheng T, Lupichuk SM, Nodwell MJ, Russell JA,
Auer IA, Morris DM. Reovirus oncolysis as a novel purging strategy for autologous stem cell
transplantation. Blood 2003; 102: 377-387.
Abrey A, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, Paleologos N, Correa
DD, Anderson ND, Caron D, Zelenetz A, Nimer SD, DeAngelis LM. Intensive Methotrexate and
Cytarabine Followed by High-dose Chemotherapy with Autologous Stem Cell Rescue in Patients
with Newly Diagnosed Primary CNS Lymphoma: An Intent to Treat Analysis. J Clin Oncol 2003;
21: 4151-4156
W Scheithauer, J McKendrick, S Begbie, M Bormer, WI Burns, HA Burris, J Cassidy, D Jodrell,
P Koralewski, EL Levine, N Marschner, J Maroun, P Garcia-Alfonso, J Tujakowski, G van
Hazen, A Wong, J Zaluski, C Twelves. Oral Capecitabine as an alternative to IV 5-Fluorouracilbased adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial. Annals
of Oncology 14:1735-1743, 2003.
PEER REVIEWED ABSTRACTS PUBLISHED IN 2003
RS Benjamin, C Rankin, C Fletcher, C Blanke, M Von Mehren, R Maki, V Bramwell, L Baker, E
Borden, GD Demetri for the Sarcoma Intergroup. Phase III dose-randomised study of imatinib
mesylate (STI 571) for GIST: Intergroup S0033 early results. Proc. Am. Soc. Clin. Oncol.
22:814, 2003.
Jay S Wunder, Nalan Gokgoz, Sasha Eskandarian, Wenqing He, Shelley B Bull, Anthony
Griffin, Soha Riad, Robert E Turcotte, Vivien H Bramwell, Robert S Bell, Rita Kandel, Irene L
Andrulis. Towards an improved classification of malignant fibrous histiocytoma. Connective
Tissue Oncology Society Annual Meeting 2003, Barcelona, Spain.
Stefan Glück, J MacKinnon, H Lau, R Syme, J Dort, D Glück, University of Calgary.
Metronomic therapy in recurrent and metastatic chemo-resistant SCCHN: Data from a pilot
study. Proc. Am. Soc. Clin. Oncol. 11:513, 2003.
Page 6 of 15
J Dancey, M Crump, Stefan Glück, D Tu, S Marlin, L Shepherd, for the NCI Canada Clinical
Trials Group. Quality of life (QOL) analysis of a randomized trial of high-dose chemotherapy
(HDCT) with peripheral stem cell transplant (PSCT) versus standard chemotherapy (SCT) in
women with metastatic breast cancer (MBC): National Cancer Institute of Canada Clinical Trials
Group study (NCIC-CTG) MA-16. Proc. Am. Soc. Clin. Oncol. 22:749, 2003.
Glück S. Editorial – Reflection and reaction: Breast cancer trial with erythropoietin terminated
unexpectedly. The Lancet Oncology, 2003: 4, 459-460.
Morris D, Forsyth P, Paterson A, Donnelly B, DeFrancesco L, Trpkov K, Coffey M. Reovirus
as a Potential Ras Pathway Therapeutic: In Vitro and In Vivo Activity, Tumour Selectivity and
Safety. Biotherapy of Cancer from Disease to Targeted Treatment, Munich Germany,
September 2003.
James A Russell, Man-Chiu Poon, A Robert Turner, Ahsan M Chaudhry, Ramakrishnan
Parameswaran, Diana Quinlan, Oluyemi Jeje, Christopher B Brown, Stefan Glück, Don Morris,
Douglas Stewart, Loree M Larratt. GVHD Mortality and Control of Leukemia in Adult
Allogeneic BMT Recipients with CML in CP1 Given Daily IV Busulfan, Fludarabine, and LowDose Antithymocyte Globulin (ATG): Comparison with Historical Experience Using BuCy2
without ATG. Blood 2003; 102 (11):Abstr 5583.
James A Russell, Ahsan M Chaudhry, Ramakrishnan Parameswaran, Diana M Quinlan,
Stefan Glück, Don Morris, Christopher Brown, Douglas A Stewart, Oluyemi Jeje, Loree M
Larratt, A Robert Turner. Outcomes of 100 Adult Matched Sibling Stem Cell Transplant (SCT)
Recipients Given Pretransplant Low-Dose Antithymocyte Globulin (ATG) and Followed for at
Least One Year. Blood 2003; 102 (11): Abstr 1734.
Ringden O, Barrett AJ, Zhang M-J, Loberiza FR, Bolwell BJ, Cairo MS, Gale RP, Hale GA, Litzow
MR, Martino R, Russell JA, Tiberghien P, Urbano-Ispizua A, Horowitz MM. Decreased treatment
failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with
high CD34 cell doses. British Journal of Haematology 2003, 121(6):874.
Kangarloo SB, Russell JA, Andersson BS, Syme RM, Quinlan D, Glück S. A test dose strategy
for pharmacokinetically guided individualized dosing of intravenous Busulfan. Blood 2003; 102
(11): 5335.
de Lima M, Couriel TM, Thaell PF, Shahjahan M, Giralt S, Anderlini P, Russell JA, Shpall EJ,
Champlin RE, Andersson BS. Once daily Busulfan (Bu) and Fludarabine (Flu) with allo stem cell
transplantation (AlloSCT) in acute myelogenous leukaemia (AML) and myelodysplastic syndrome
(MDS): Clinical results and pharmacokinetics. Blood 2003. 102(11) 2607.
Russell JA, Larratt LM, Chaudhry AM, Quinlan D, Jeje O, Brown CB, Parameswaran R, Glück
S, Morris D, Turner AR, Stewart S. Improved survival in adult allogeneic stem cell transplant
(SCT) recipients with ALL and lymphoblastic lymphoma in CR1 given daily IV Busulfan,
Fludarabine, 400 cGy TBI and low-dose antithymocyte globulin (ATG). Blood 2003. 102(11)
3604.
Stewart DA. Reports from the 44th Annual Meeting of the American Society of Hematology,
Dec 6-10, 2002: Commentary of the abstract entitled: “Rituximab plus CHOP (R-CHOP) in the
treatment of elderly patients with diffuse large B-cell lymphoma (DLBCL) overcomes bcl-2
associated chemotherapy resistance.” Oncology Exchange 2003; 2:34-35.
Page 7 of 15
Andrew Belch, Alexander McEwan, Joanne Hewitt, Douglas Stewart, Reinhard Kloiber,
Stephanie Hubbard, Michael Stabin, Aaron Brill, Gilles Gallant, Blake Lara, Jerry Klein. Early
Clinical Data for LymphoRad-131 (LR131; Iodine I-131 Labeled B-Lymphocyte Stimulator) in
Patients with Relapsed/Refractory Non-Hodgkin s Lymphoma. Blood 2003;102 (11): Abstr1481.
Rachel Syme, Ron Bajwa, Doug Stewart and Stefan Glück. CD34 positive cells are a better
cellular source for generating dendritic cells from mobilized peripheral blood than monocytes.
94th Annual Meeting Proceedings, 2003, Proceedings of the American Association for Cancer
Research, 44:414, #1825.
Francis P, Fleming G, Nasi ML, Pagani O, Perez E, and Walley B. Tailored Treatment
Investigations for Premenopausal Women with Endocrine Responsive (ER+ and/or PgR+)
Breast Cancer: The SOFT, TEXT, and PERCHE Trials. Abstracts from the 8th International
Conference on “Primary Therapy of Early Breast Cancer” - St. Gallen, Switzerland, #104, 2003.
C Twelves, A Wong, M Nowachi, J Cassidy, A Cervantes, H Kroning, J McKendrick, G Van
Hazel, W Scheithauer. Improved safety results of a phase III trial of Capecitabine vs. bolus 5FU/Leucovorin as adjuvant therapy for colon cancer (the X-Act Study). Proc. Am. Soc. Clin.
Oncol. 22:294, 2003.
A Chan, A Wong, D Jenken, J Heine, D Johnson, D Buie. Post treatment TNM staging is a
prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiation. Int. J. Rad. Oncol. Biophys. 57 (Suppl.1) 181, 2003.
M Nowacki, H Kroning, A Cervantes, F Husseini, J McKendrick J. Schuller, C Twelves, A
Wong, J Zaluski, J Douillard. Improved safety of Capecitabine vs. bolus 5-FU / Leucovorin (LV)
as adjuvant therapy for colon cancer. Eur. J. Cancer 39 (Suppl.5) 326, 2003.
BOOK CHAPTERS
Paterson AHG. The place of bisphosphonates in the management of breast cancer. In
“Medical Therapy in Breast Cancer” Cha 13: pp 340-352. Edited by Zenon Rayter and Janine
Mansi. Cambridge University Press (2003).
Paterson, AHG. The Place of Bisphosphonates in the Management of Breast Cancer. In
Breast Cancer Management: Application of Evidence to Patient Care. Second Edition Part 4;
Section 1; pp 463-474. Edited Nabholtz JM, Tonkin K, Reese DM, Aapro MS, Buzdar AU.
Published Lippincott, Williams and Wilkins, Philadelphia, Baltimore, New York, London, 2003.
Paterson AHG, Lindsay M. Erythropoietin in the Management of Cancer Patients. In Breast
Cancer Management: Application of Evidence to Patient Care. Second Edition Part 4; Section
1; cha 33: pp 457-462. Edited Nabholtz JM, Tonkin K, Reese DM, Aapro MS, Buzdar AU.
Published Lippincott, Williams and Wilkins, Philadelphia, Baltimore, New York, London, 2003.
(Non-peer Reviewed)
Paterson AHG, Powles TJ.
Bone Metastases From Breast Cancer:
The role of
Bisphosphonates in Prevention. In Breast Cancer: Edited Osborne K. (to be published 2004)
Page 8 of 15
Tonkin K, Stewart D, Glück S: Hematopoietic growth factor support in breast cancer. In
Nabholtz J-M, Tonkin K, Reese DM, Aapro MS, Buzdar AU (Eds): Breast Cancer Management:
Application of Clinical and Translational Evidence to Patient Care. Second Edition. Lippincott
Williams and Wilkins, Philadelphia, PA, 2003, pp 447-456.
NATIONAL/INTERNATIONAL LECTURES:
Dr. Vivien Bramwell
Invited Speaker. “Histology specific sarcoma regimens”.
Biannual Meeting, San Diego, California.
South West Oncology Group –
Invited Speaker. “Taxane and dose dense adjuvant chemotherapy for breast cancer: where
does MA 21 fit?” Grand Rounds, Halifax, Nova Scotia.
Planning Committee Participant. Progress Review Group in Sarcoma, US
April: Planning meeting, Bethesda, Maryland
October: Roundtable meeting, Philadelphia, Pennsylvania.
Dr. Cynthia Card
Poster Presentation. “Anemia as a Prognostic Factor in Induction Chemotherapy for Stage IIIA
N2 Non Small Cell Lung Cancer”. CM Card, RL Burkes, RJ Ginsberg, FA Shepherd, ME
Blackstein, S Farooq. World Congress on Lung Cancer, Vancouver, BC.
Dr. Scot Dowden
Invited Speaker. “Emerging Therapies in Colorectal Carcinoma”. Western Canadian Colorectal
Cancer Consensus Conference, Winnipeg, MB, September 2003.
Invited Speaker. “Chemotherapy Induced Nausea”. Cancer Care Saskatchewan, Saskatoon,
SK, September, 2003.
Invited Speaker. “Internet Based CME ‘oncologyforum.ca’”. Canadian Association of Medical
Oncologists AGM, Toronto, ON, October 2003.
Dr. Desirée Hao
Discussant. “Novel Therapies in Lung Cancer: how do we hit the bull’s eye?” 10th World
Conference on Lung Cancer. Vancouver, BC, August 12, 2003.
Dr. Peter Forsyth
Presentation. “Evaluation of Reovirus as an Oncolytic Agent in Brain Tumors”. The Second
International Meeting on Replicating Oncolytic Virus Therapeutics, Alberta Cancer Foundation,
Banff, AB, March 26, 2003.
Invited Speaker. “Using a Scourge to Treat a Devil: Oncolytic Viruses as Experimental
Therapeutics in Brain Tumors”. Canadian Congress of Neurological Sciences, Quebec City,
Quebec, June 18, 2003.
Page 9 of 15
Invited Speaker. “Asking lab questions in the clinic and clinical questions in the lab: reovirus
and invasion in gliomas”. University of Ottawa, Department of Biochemistry, Microbiology and
Immunology, Ottawa, ON, December 3, 2003,
Dr. Stefan Glück
Invited Lecturer: US Oncology, Greenville, South Carolina, USA, January 15-16, 2003.
Invited Speaker: 3rd Annual Breast Cancer Advisory Board, Telluride, Colorado, USA, January
30-February 2, 2003.
Invited Lecturer: Various Locations, Asia, February 5-17, 2003.
Invited Speaker: “Breast Cancer: Adjuvant Treatment”. Denver, Colorado, USA, February 21,
2003.
Invited Speaker: “Breast Cancer: Adjuvant Treatment”. Dallas, Texas, USA, March 6, 2003.
Invited Speaker: Support Care Conference, Bermuda, March 14-16, 2003.
Invited Speaker: Pfizer Oncology Key Opinion Leaders Think Tank, San Diego, CA, USA, May
16-18, 2003.
Invited Speaker: Femara Advisory Board Meeting, Chicago, IL, USA, May 31, 2003.
Invited Speaker: CME, Tumor Conference, S. Florida, USA, June 19, 2003.
Invited Speaker: Regional Meeting, International Oncology Network, Wichita, Kansas, USA,
July 11-12, 2003.
Invited Speaker: 6th University of Texas MD Anderson Cancer Center Investigators’ Workshop,
Amelia Island, Florida, USA, July 16-20, 2003.
Invited Lecturer: Primeras Jornadas de Oncologia del Sureste, Mexico, July 31-August 3, 2003.
Dr. Don Morris
Invited Speaker. “Iressa”. 3rd International World Lung Meeting – AstraZeneca Symposium,
Vancouver, BC, August 2003.
Presentation. 2nd Biannual GIST Investigators Meeting, Helsinki, Finland, September 2003.
Invited Speaker. “Reovirus as a Cancer Therapeutic”.
Meeting, Munich, Germany, 2003.
Invited Speaker. “The role of Darbopoeitin in Cancer”.
Hungary, October 2003.
Page 10 of 15
3rd Annual Biotherapy of Cancer
Amgen Symposium, Budapest,
Dr. Alexander Paterson
Invited Speaker. “Bisphosphonates and Cancer”. Israeli Society of Oncology, Eilat, Israel,
January 2003.
Moderator/Host. Erythropoietin Focus Group Meeting - Ortho Biotech, Saskatoon, SK, February
12, 2003.
Invited Lecturer. “Breast Cancer and Therapies”. Lecture Series:
Guangzhou, Shanghai; Beijing, China, February 2003.
Chiang Mai, Thailand;
Invited Speaker. “Preventing Skeletal Complications and Metastases in Primary Breast
Cancer”. Helsinki, Finland, April 5, 2003.
Invited Speaker. “Bone Metastases: From the Bench to the Bedside”. Education Session,
American Society of Clinical Oncology 2003 Annual Meeting, Chicago, Illinois, USA, May 30June 3, 2003.
Invited Speaker. “Malignant Bone Disease, Zoledronate and NSABP B-34”. Annual Scientific
Session, NSABP, Orlando, Florida, USA, June 28, 2003.
Invited Lecturer.
“Bisphosphonates and Cancer”.
Lecture Series - South Africa:
Johannesburg, Durban, Cape Town, South Africa, September 2-6, 2003.
Invited Speaker. “Bisphosphonates and Cancer”. Cleveland Clinic Health System, Moreland
Hills, Ohio, USA, September 11, 2003.
Invited Speaker. “Bisphosphonates in Breast Cancer – A New Era”. Aultman Health
Foundation Third Annual Cancer Conference, Canton, Ohio, USA, September 12, 2003.
Invited Speaker. “Establishing the Role and Benefits of Anti-Host Cell Agents in Cancer”.
ECCO Symposium, Copenhagen, Denmark, September 24, 2003.
Visiting Lecturer. “Bisphosphonates and Cancer”. Lecture Series – Slovenia, October 22-26,
2003.
Presentation. “Update on NSABP B-34 and the Replacement Trial”. NSABP Principal
Investigator’s Meeting, Huntingdon Beach, California, USA, November 9, 2003.
Visiting Speaker. “The Vicious Cycle in Bone Metastases and Research Opportunities”, and
“Pathophysiology of Bone Metastases and Research Opportunities”. The Vivian Saykaly
Visiting Professor in Medical Oncology, McGill University Health Centre, Montreal, Canada,
December 10, 2003.
Dr. James Russell
Visiting Speaker. “Outpatient Allogeneic Transplantation”. Tandem BMT Meetings, Keystone,
Colorado, USA, January 29-February 4, 2003.
Invited Speaker.
“Low dose Thymoglobulin in Allogeneic Stem Cell Transplantation”.
Washington University, St. Louis, USA, February 13, 2003.
Page 11 of 15
Invited Speaker. “Acute and Chronic GVHD and HLA Matched Sibling Transplants – Can we
Further Improve the Outcomes?” Hematology Clinical Advisory Meeting, Laguna Niguel, Los
Angeles, CA, USA, March 7, 2003.
Visiting Speaker. “Once Daily Intravenous Busulfan”.
Michigan, USA, March 14, 2003.
University of Michigan, Ann Arbor,
Visiting Speaker. “Bone Marrow/Stem Cell Transplantation”. ASH 2002 Highlights Conference,
Washington Hospital Centre, Washington Cancer Institute, Washington, DC, USA, March 20,
2003.
Invited Speaker. “Acute and Chronic GVHD in HLA Matched Sibling Transplants – Can We
Further Improve the Outcomes?”
Hematology Clinical Advisory Meeting, Boston,
Massachusetts, USA, April 25, 2003.
Visiting Speaker. “Once Daily Intravenous Busulfan as Conditioning for Allogeneic Stem Cell
Transplantation”. University of Texas, San Antonio, Texas, USA, May 22, 2003.
Visiting Speaker. “Once Daily Intravenous Busulfan as Conditioning for Allogeneic Stem Cell
Transplantation”. University of Manitoba Health Sciences Centre, Winnipeg, Manitoba, June 20,
2003.
Dr. Barbara Walley
Visiting Speaker. “TEXT Trial”. BCSG/NCIC CTG Adjuvant Breast Cancer Investigator
Meeting, Chicago, Illinois, USA, June 1, 2003.
Visiting Speaker. “Premenopausal Hormone Responsive Breast Cancer Trials (SOFT, TEXT,
PERCHE)”. CAMO Pfizer Dinner Satellite Symposium, Toronto, ON, October 16, 2003.
GRANTS CURRENT IN 2003
Dr. Vivien Bramwell
1999 – 2004
National Cancer Institute of Canada
Support for NCIC-Clinical Trials Group
Principal Investigator: J. Pater
Co-Investigator: V. Bramwell
3.1M, Yr. 1
3.4M, Yr. 2
3.5M, Yr. 3-5
2001 – 2003
Canadian Institutes of Health Research
The process and outcomes of care for soft tissue sarcoma of the extremeties
Principal Investigator: L. Paszat
Co-Investigator: V. Bramwell
216,439
Page 12 of 15
2001 – 2004
Canadian Breast Cancer Research Initiative
Osteopontin and breast cancer: functional contribution to malignancy and potential as a plasma
and tumor marker of progression
Principal Investigator: A. Chambers
Co-Investigator: V. Bramwell
402,173
2001 – 2006
Canadian Institutes of Health Research
Interdisciplinary Health Research Team (IHRT) in musculoskeletal neoplasia
Principal Investigator: R. Bell
Co-Investigator: V. Bramwell
1,199,597/Yr.
2002 – 2003
Canadian Breast Cancer Foundation, Ontario Chapter
Predicting response to treatment and outcome in metastatic breast cancer: A comparison
between a novel circulating tumor marker (osteopontin) and clinically approved serum markers
(CEA, CA 15.3, ECD/HER-2)
Principal Investigator: V. Bramwell
93,078
2003 – 2007
Canadian Breast Cancer Research Initiative
An explanatory trial of breast cancer prevention
Principal Investigator: N. Boyd
Co-Investigator: V. Bramwell
(Renewal for further 4 years.)
1,052,453
Dr. Scott Ernst
2000 – 2003
National Cancer Institute of Canada
Randomized controlled trial to compare efficacy and safety of cryotherapy and radiation therapy
in conjunction with neoadjuvant hormone therapy for the treatment of localized prostate cancer
Principal Investigator: S. Ernst
642,291
Dr. Peter Forsyth
2001 – 2003
The Kid’s Cancer Care Foundation
Oncolysis in Pediatric Brain Tumors
Principal Investigator: P. Forsyth
60,000/Yr.
Page 13 of 15
2001 – 2003
Alberta Cancer Board
The Provincial Clinical Research Program (PCRPAC)
Phase I study of high dose tamoxifen, conformal radiation therapy and escalating doses of oral
topotecan for malignant gliomas
Principal Investigator: P. Forsyth
53,515/Yr.
2001 – 2004
Alberta Cancer Board
Comprehensive management of patients with malignant brain tumor. The Alberta Brain Tumor
Program
Principal Investigator: P. Forsyth
132,285/Yr.
2002 – 2004
The Cancer Research Society
Molecular and cellular characterization of glioma invasion
Principal Investigator: P. Forsyth
60,000/Yr.
2002 – 2006
Canadian Institutes for Health Research
Evaluation of reovirus as an oncolytic agent in medulloblastomas
Principal Investigator: P. Forsyth
80,646/Yr.
2002 – 2006
National Cancer Institute of Canada
Reovirus as an oncolytic agent in human malignant gliomas (MG)
Principal Investigator: Dr. P. Forsyth
224,250 Yr. 1
154,250 Yr. 2-4
Dr. Stefan Glück
2002 – 2003
Alberta Cancer Board
Development of a clinically applicable cellular based immunotherapy program
Principal Investigator: Dr. S. Glück
25,000
2001 – 2003
Alberta Cancer Foundation
DRD-15, Pharmacokinetic Labs
Principal Investigator: S. Glück
300,000
Page 14 of 15
2002 – 2003
Alberta Cancer Foundation
Dendritic cell immunotherapy/COX–2 expression in squamous cell carcinoma – high speed
centrifuge
Principal Investigator: S Glück
10,000
Dr. Don Morris
1999 – 2003
Alberta Cancer Foundation
DRD-13 TBCC Translational Research Laboratory
Principal Investigator: S. Glück, D. Morris, A. Magliocco
252,000
2002 – 2003
Oncolytics Biotech Inc.
Laboratory correlate studies for prostate reovirus phase II trial
Principal Investigator: D. Morris
134,625
2002 – 2003
Oncolytics Biotech Inc.
Phase II reovirus and prostate clinical trial
Principal Investigator: D. Morris
165,593
Page 15 of 15